Page last updated: 2024-09-04

3,4-dihydro-5-methyl-1(2h)-isoquinolinone and topotecan

3,4-dihydro-5-methyl-1(2h)-isoquinolinone has been researched along with topotecan in 1 studies

Compound Research Comparison

Studies
(3,4-dihydro-5-methyl-1(2h)-isoquinolinone)
Trials
(3,4-dihydro-5-methyl-1(2h)-isoquinolinone)
Recent Studies (post-2010)
(3,4-dihydro-5-methyl-1(2h)-isoquinolinone)
Studies
(topotecan)
Trials
(topotecan)
Recent Studies (post-2010) (topotecan)
16022,392626792

Protein Interaction Comparison

ProteinTaxonomy3,4-dihydro-5-methyl-1(2h)-isoquinolinone (IC50)topotecan (IC50)
Cytochrome P450 3A4Homo sapiens (human)1.5211
DNA topoisomerase 1Homo sapiens (human)0.8525
DNA topoisomerase 2-alphaHomo sapiens (human)0.605
DNA topoisomerase 2-betaHomo sapiens (human)0.605
Hypoxia-inducible factor 1-alphaHomo sapiens (human)0.06
Multidrug and toxin extrusion protein 2Homo sapiens (human)8.6
Multidrug and toxin extrusion protein 1Homo sapiens (human)1.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.17

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almassy, RJ; Boritzki, TJ; Calabrese, CR; Calvert, AH; Curtin, NJ; Ekkers, A; Golding, BT; Griffin, RJ; Hostomsky, Z; Kumpf, RA; Kyle, S; Li, J; Maegley, KA; Newell, DR; Thomas, HD; Tikhe, JG; Wang, LZ; Webber, SE; Yu, XH; Zhang, C1

Other Studies

1 other study(ies) available for 3,4-dihydro-5-methyl-1(2h)-isoquinolinone and topotecan

ArticleYear
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.
    Journal of medicinal chemistry, 2004, Oct-21, Volume: 47, Issue:22

    Topics: Antineoplastic Agents; Azepines; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Models, Molecular; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Topoisomerase I Inhibitors

2004